Yantai Biomedical Health Industry Development Group Co., Ltd., a wholly-owned subsidiary of Yantai Guofeng Investment Holding Group Co., Ltd., has recently been assigned a corporate credit rating of AA+ with a stable outlook by Golden Credit Rating International Co., Ltd.

This rating represents authoritative recognition from the capital market of the biomedical group's comprehensive strength, governance standards, debt-servicing capacity, and growth prospects, fully underscoring the sound credit profile and stable operations of this municipal state-owned enterprise.

Going forward, the biomedical group will leverage the advantages of its AA+ rating to broaden financing channels and lower financing costs, while continuing to strengthen biomedical industry investment and park operations. This will provide solid support for the high-quality development of the city's biomedical industry.

Yantai Biomedical Health Industry Development Group Co., Ltd.

Established in July 2021 in accordance with the requirements of the Minutes of the Special Meeting on Industrial Chain Work of the Yantai Municipal Government, Yantai Biomedical Health Industry Development Group Co., Ltd. is a wholly-owned subsidiary of Yantai Guofeng Investment Holding Group Co., Ltd., with a registered capital of 1.5 billion yuan. As outlined in the Implementation Plan for the "Chain Leader System" of Yantai's Biomedical Industry Chain, the group serves as the "One Platform", responsible for integrating the city's biomedical research platforms, public service platforms, and investment and financing management platforms. It establishes and refines a service system to support industrial development, and undertakes functions including the development and construction of industrial parks, industrial layout planning, operational management, project investment promotion, and public services.

Since October 2021, with strong support from the Yantai Municipal Party Committee and Government, the Municipal State-owned Assets Supervision and Administration Commission, and Guofeng Group, the biomedical group has adopted "Yantai Blue Pharma Valley" as its park brand. It has been advancing the construction of industrial parks to a high standard and, within Yantai's "1+3+X" life sciences innovation core area, has taken the lead in creating Yantai Blue Pharma Valley · Life Island — a market-oriented, industrialization-supported, high-end R&D-based life sciences industrial park, the only one in China to feature a closed-loop vertical ecosystem.

The park covers a planned area of 3.2 square kilometers, with a total floor area of 1.3 million square meters and a total investment of 12 billion yuan. It follows a layout of "one area, three parks, and four islands": the Northern Island serves as a high-end R&D and lifestyle support zone; the Eastern Island hosts the Cell and Regenerative Medicine Industrial Park; the Southern Island houses the Medical Isotopes and Radiopharmaceuticals Industrial Park; and the Western Island is under planning. With market cooperation, concentrated supporting facilities, and professional services as its core competitiveness, the park chains together industries, invigorates the area with production, and attracts investment to drive growth, all contributing to the vision of building Yantai into an international model city for life sciences innovation.